ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections
August 14 2018 - 5:00PM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced that Cara Cassino, M.D., the
Company's Executive Vice President of Research and Development and
Chief Medical Officer, has been invited by the Food and Drug
Administration (FDA) to participate in a panel discussion for a
public workshop entitled “Development of Non-Traditional Therapies
for Bacterial Infections”. The public workshop will be held August
21st, 2018 and August 22nd, 2018 at the FDA’s White Oak campus in
Silver Spring, MD. The purpose of the public workshop is to discuss
the general development considerations of non-traditional
therapies, including pre-clinical development, early clinical
studies, and phase 3 clinical trial designs to evaluate safety and
efficacy. Dr. Cassino will provide industry perspective on the
development of lysin therapeutics to treat bacterial infections.
A live webcast of the public workshop will be
available on the FDA website at
https://collaboration.fda.gov/dcontpfbi/. A recording of the
workshop will be available shortly after the completion of the
workshop, and transcripts will be available approximately 45 days
after the workshop.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-Resistant
Staphylococcus aureus) and influenza. ContraFect’s lead product
candidate, CF-301, is currently in a Phase 2 clinical trial for the
treatment of Staphylococcus aureus (Staph aureus) bacteremia,
including endocarditis and is the first lysin to enter clinical
studies in the U.S. ContraFect is also conducting research focused
on the discovery of lysins to target Gram-negative bacteria.
About CF-301 (exebacase):
CF-301 (exebacase) is a recombinant bacteriophage-derived lysin
with potent bactericidal activity against Staph aureus, a major
cause of blood stream infections, or bacteremia. CF-301 has the
potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus and does not impact the
body's natural bacterial flora. By targeting a conserved region of
the cell wall that is vital to bacteria, resistance is less likely
to develop to CF-301. Combinations of CF-301 with standard of care
antibiotics significantly increased bacterial killing and survival
in animal models of disease when compared to treatment with
antibiotics or CF-301 alone. In addition, in vitro and in vivo
experiments have shown that CF-301 is highly active against
biofilm-associated infections. CF-301 was licensed from The
Rockefeller University and is being developed at ContraFect. It is
the first lysin to enter clinical studies in the U.S.
Forward-Looking Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding our ability to discover
and develop protein and antibody therapeutics for life-threatening,
drug-resistant infectious diseases, statements made regarding the
FDA, its public workshop and information provided by Dr. Cassino,
our ability to address life threatening infections using our
therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses, whether our initial product candidates can treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza, our ability to continue research
focused on lysins targeting Gram-negative bacteria, whether CF-301
has potent bactericidal activity against Staph aureus and whether
it has the potential to be a first-in-class treatment for Staph
aureus bacteremia, and statements regarding CF-301 data, including
its activity regarding biofilm-associated infections.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange Commission.
Actual results may differ from those set forth in the
forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024